These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2779475)

  • 21. Tetrahydroaminoacridine blocks voltage-dependent ion channels in hippocampal neurons.
    Rogawski MA
    Eur J Pharmacol; 1987 Oct; 142(1):169-72. PubMed ID: 2446884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tetrahydroaminoacridine blocks potassium channels and inhibits sodium inactivation in Myxicola.
    Schauf CL; Sattin A
    J Pharmacol Exp Ther; 1987 Nov; 243(2):609-13. PubMed ID: 2445954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-activity investigation of the alteration of the physical state of the skeletal network of proteins in human erythrocyte membranes induced by 9-amino-1,2,3,4-tetrahydroacridine.
    Palmieri DA; Butterfield DA
    Biochim Biophys Acta; 1990 May; 1024(2):285-8. PubMed ID: 2354181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of rat brain histamine-N-methyltransferase by 9-amino-1,2,3,4-tetrahydroacridine (THA).
    Cumming P; Reiner PB; Vincent SR
    Biochem Pharmacol; 1990 Sep; 40(6):1345-50. PubMed ID: 2403387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tetrahydroaminoacridine and other allosteric antagonists of hippocampal M1 muscarine receptors.
    Potter LT; Ferrendelli CA; Hanchett HE; Hollifield MA; Lorenzi MV
    Mol Pharmacol; 1989 May; 35(5):652-60. PubMed ID: 2725474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of Alzheimer's disease with short- and long-term oral THA and lecithin: a double-blind study.
    Fitten LJ; Perryman KM; Gross PL; Fine H; Cummins J; Marshall C
    Am J Psychiatry; 1990 Feb; 147(2):239-42. PubMed ID: 2405720
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory effect of 9-amino-1,2,3,4-tetrahydroacridine (THA) on the potassium current of rabbit sinoatrial node.
    Kotake H; Hisatome I; Matsuoka S; Miyakoda H; Hasegawa J; Mashiba H
    Cardiovasc Res; 1990 Jan; 24(1):42-6. PubMed ID: 2328513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Canadian collaborative study of tetrahydroaminoacridine (THA) and lecithin treatment of Alzheimer's disease: effect on mood.
    Vida S; Gauthier L; Gauthier S
    Can J Psychiatry; 1989 Apr; 34(3):165-70. PubMed ID: 2655861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tetrahydroaminoacridine improves the spatial acquisition deficit produced by nucleus basalis lesions in rats.
    Kwo-On-Yuen PF; Mandel R; Chen AD; Thal LJ
    Exp Neurol; 1990 Jun; 108(3):221-8. PubMed ID: 2351210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tetrahydroaminoacridine modulates technetium-99m labelled ethylene dicysteinate retention in Alzheimer's disease measured with single photon emission computed tomography imaging.
    Riekkinen P; Kuikka J; Soininen H; Helkala EL; Hallikainen M; Riekkinen P
    Neurosci Lett; 1995 Jul; 195(1):53-6. PubMed ID: 7478254
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tetrahydroaminoacridine or THA. Disputed value in Alzheimer's type dementia].
    Chatellier G
    Rev Prat; 1993 Mar; 43(6):725-8. PubMed ID: 8341950
    [No Abstract]   [Full Text] [Related]  

  • 32. Tacrine: first drug approved for Alzheimer's disease.
    Crismon ML
    Ann Pharmacother; 1994 Jun; 28(6):744-51. PubMed ID: 7919566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrine, a drug with therapeutic potential for dementia: post-mortem biochemical evidence.
    Francis PT; Bowen DM
    Can J Neurol Sci; 1989 Nov; 16(4 Suppl):504-10. PubMed ID: 2572313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 9-Amino-1,2,3,4-tetrahydroacridine (THA) blocks agonist-induced potassium conductance in rat hippocampal neurones.
    Halliwell JV; Grove EA
    Eur J Pharmacol; 1989 Apr; 163(2-3):369-72. PubMed ID: 2721578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress report on the Canadian Multicentre Trial of tetrahydroaminoacridine with lecithin in Alzheimer's disease.
    Gauthier S; Bouchard R; Bacher Y; Bailey P; Bergman H; Carrier L; Charbonneau R; Clarfield M; Collier B; Dastoor D
    Can J Neurol Sci; 1989 Nov; 16(4 Suppl):543-6. PubMed ID: 2680009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical experience with and side-effects of tacrine hydrochloride in Alzheimer's disease: a pilot study.
    Forsyth DR; Surmon DJ; Morgan RA; Wilcock GK
    Age Ageing; 1989 Jul; 18(4):223-9. PubMed ID: 2683619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tetrahydroaminoacridine facilitates passive avoidance learning in rats with nucleus basalis magnocellularis lesions.
    Dokla CP; Parker SC; Thal LJ
    Neuropharmacology; 1989 Nov; 28(11):1279-82. PubMed ID: 2687717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of tacrine hepatotoxicity in patients with Alzheimer disease or AIDS].
    Fredj G; Dietlin F; Barbier G; Jasmin C; Bonhomme L; Esctein S; Misset JL; Meyer P; Kalifa D; Beugre T
    Therapie; 1992; 47(3):245-7. PubMed ID: 1295125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Heterogeneity of adverse hepatic reactions to tetrahydroaminoacridine.
    Ames DJ; Bhathal PS; Davies BM; Fraser JR; Gibson PR; Roberts S
    Aust N Z J Med; 1990 Apr; 20(2):193-5. PubMed ID: 2344330
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of acute arecoline, tacrine and arecoline + tacrine post-training administration on retention in old mice.
    Flood JF; Cherkin A
    Neurobiol Aging; 1988; 9(1):5-8. PubMed ID: 3380255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.